arrow
P

Paul A. Hamlin

Memorial Sloan Kettering Cancer Center
H指数:47
被引数:8,185

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma

晚期高级别B细胞淋巴瘤的临床结局、复发模式和分子景观

2026-07-130
OA
Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma

二十年单机构数据揭示复发/难治性伯基特淋巴瘤的罕见长期生存者

2026-01-011
OA
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era

利妥昔单抗时代原发性皮肤弥漫大B细胞淋巴瘤,腿型的治疗效果和CNS复发风险

2025-08-290
OAAI
Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Pembrolizumab和Entinostat治疗复发/难治性霍奇金淋巴瘤的II期试验最终应答和生存结果

BLOOD
IF23.1
2024-11-051
PRE
Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma- International, Multi-Center Real-World Experience

Brentuximab Vedotin为基础的方案用于新诊断经典型霍奇金淋巴瘤的老年患者——国际、多中心真实世界经验

BLOOD
IF23.1
2024-11-050
PRE
Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes

分子特征与弥漫性大B细胞淋巴瘤的疾病分期相关,并揭示了患者预后的异质性。

BLOOD
IF23.1
2024-11-050
PRE
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

具有MYC,BCL2和/或BCL6重排的有限阶段高级别b细胞淋巴瘤: BCL2重排导致不良结果

2024-10-140
OAAI
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience

利妥昔单抗和来那度胺治疗复发或难治性惰性非霍奇金淋巴瘤的现实经验

2024-09-050
OAAI
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation (vol 109, pg 1149, 2024)

免疫化学疗法联合来那度胺治疗高危套细胞淋巴瘤,并进行可测量的残留疾病评估 (109卷,1149页,2024页)

2024-08-010
OAAI
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
2024-04-280
OAAI
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes
2023-08-312
OAAI
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
2023-08-312
OAAI
Retrospective characterization of nodal marginal zone lymphoma
2023-08-244
OAAI
Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma
2023-07-137
OAAI
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
2023-01-010
OAAI
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
2022-06-30101
OA
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
2022-02-102
OAAI